# Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

> **NCT06268327** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cisplatin injection and gemcitabine
- **DRUG:** Capecitabine tablets

## Key facts

- **NCT ID:** NCT06268327
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2025-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06268327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06268327, "Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06268327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*